Reversal of Idiopathic Thrombocytopenic Purpura [ITP] with Fecal Microbiota Transplantation [FMT]

Adverse events in faecal microbiota transplant: a review of the literature

“…In addition the follow up period was highly variable from about 1 week (100) to 15 years. (112) FMT has been applied beyond the treatment of CDI where its use is well established, to ulcerative colitis (10,83,84,(87)(88)(89)(90)(91)(92)(93)(94)(95)(96)(97)(98)(99) Crohn's disease (92,(100)(101)(102)(103)(104)(105)(106)(107) and mixed IBD. (109) Pioneering application in patients with constipation, (105,112) metabolic syndrome (9) and IBS (105,111) has been reported, raising questions as to the exact pathophysiology of these conditions.…”

“…Use in all forms IBD is the second most commonly reported indication for FMT, though the numbers of patients are small, 278 (17.8%). Some authors reporting successful outcomes (89,98,99,102,103,106,107,109,110) while others are more guarded, reporting more variable results or no discernible improvement. (10,91,93,101,104) In a relapsing and remitting condition the significance of adverse events such as flares and deteriorations are difficult to delineate the natural history of the disease.…”

“…Excluding the RCT for UC previously discussed, (9) 226 of the 1555 ascertained underwent FMT primarily for inflammatory bowel disease. Amongst these were 159 procedures for ulcerative colitis (83,(87)(88)(89)(90)(91)(92)(93)(94)(95)(96)(97)(98)(99)(100) and 67 for Crohn's. (92,(100)(101)(102)(103)(104)(105)(106)(107) In addition eight patients underwent FMT for pouchitis following restorative proctocolectomy for ulcerative colitis, (108) three for mixed UC/Crohns (109) or IBD unspecified.…”

“…(110) Concomitant CDI was present in 6 patients. (90,93) Publications ranged from four single case reports (99,106,107,110) to series ranging from 3 (97,109) to 62 patients. (89)…”

Fecal microbiota transplantation as a tool to treat and reduce susceptibility to disease in animals

“…Over recent years, FMT has moved into more mainstream use in hospitals and clinics as a highly successful treatment option for recurrent Clostridium difficile infections nonresponsive to antimicrobials (Hota et al, 2018;Orenstein et al, 2013). Although C. difficile infections are the most common condition currently being treated by FMT in the developed world, many other conditions have demonstrated a positive response to experimental FMT therapy, such as chronic fatigue syndrome, idiopathic thrombocytopenic purpura, and insulin sensitivity in patients with metabolic syndrome (Borody et al, 2011(Borody et al, , 2012Vrieze et al, 2012). For the vast majority of diseases, the exact mechanism for FMT efficacy is unknown, but is likely the result of increased microbial diversity, enhanced numbers of beneficial microbial populations, and modulation of the immune system.…”